1. Shen L#, Li S#, Zhu Y#, Zhao J#, Tang X#, Li H, Xing H, Lu M, Frederick C, Huang C, Wong G*, Wang C*, Lan J*. Clinical and Laboratory-Derived Parameters of 119 Hospitalized Patients with Coronavirus Disease 2019 in Xiangyang, Hubei Province, China. J Infect. 2020 Apr 10. pii: S0163-4453(20)30166-3. (Co-Corresponding Author).
2. Shen L#, Wang C#, Zhao J#, Tang X#, Shen Y#, Lu M, Ding Z, Huang C, Zhang J, Li S, Lan J*, Wong G*, Zhu Y*. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. Emerg Microbes Infect. 2020 Dec;9(1):1096-1101. (Co-Corresponding Author).
3. Kuo S, Lan J*. Progress on Research Tools of Coronaviruses. Chinese Journal of Virology, 2020 (02): 306–313. (Corresponding Author).
4. Yang R#, Lan J#, Huang B, A R, Lu M, Wang W, Wang W, Li W, Deng Y*, Wong G*, Tan W*. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine. 2020 Jul 21; 58:102890. (Co-First Author;).
5. Lan J#, Deng Y, Song J, Huang B, Wang W, Tan W*. Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus. Virol Sin. 2018 Oct;33(5):453-455. (Co-First Author).
6. Deng Y#, Lan J#, Bao L#, Huang B, Ye F, Chen Y, Yao Y, Wang W, Qin C, Tan W*. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018 Apr 4;7(1):60. (Co- First Author).
7. Lan J#, Yao Y#, Deng Y#, Hu Y, Bao L, Huang B, Yan J, Gao GF, Qin C, Tan W*. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.Vaccine.2017 Jan (3);35(1):10-18. (Co-First Author).
8. Liu WJ#, Lan J#, Liu K#, Deng Y#, Yao Y#, Wu S, Chen H, Bao L, Zhang H, Zhao M, Wang Q, Han L, Chai Y, Qi J, Zhao J, Meng S, Qin C, Gao GF*, Tan W*. Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8+ T Cell Epitopes and Host MHC.J Immuno.2017 Jan 15;198(2):873-882. (Co-First Author).
参与申请专利:
1. 专利名称:《一种编码MERS-CoV棘突蛋白的重组41型腺病毒载体疫苗》;申请号:201510109559.2
2. 专利名称:《基于优化MERS-CoV棘图蛋白编码基因的重组5型腺病毒载体疫苗》;申请号:201510109558.8
3. 专利名称:《重组NTD蛋白亚单位疫苗对抗MERS-CoV感染》;申请号:201510431510.9
4. 专利名称:《以流感病毒M1为核心的MERS-CoV嵌合型VLPs疫苗的研制》;申请号:201610438896.0
5. 专利名称:《一种新冠肺炎疫苗以及疫苗套件》;申请号:202011406211.7